Frontage Promotes Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services
EXTON, Pa., March 31, 2026 – Frontage Holdings Corporation announces the promotion of Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services, effective March 2026. In this role, Dr. Tang will continue to lead the bioanalytical operations, with a focus on mass spectrometry-based platforms, further strengthening scientific excellence, operational efficiency, regulatory compliance, and innovation across Frontage’s service platform.
Dr. Tang has been with Frontage since 2008, joining as a laboratory scientist and progressing through a series of leadership roles with increasing responsibility. Over nearly two decades, he has established himself as a highly effective leader with strong managerial and interpersonal skills. He has played a key role in advancing Frontage’s bioanalytical capabilities, including driving the implementation of paperless bioanalytical workflows and modernizing laboratory operations. Under his leadership, the Mass Spectrometry Services team has consistently delivered strong performance and remains a key contributor to the Company’s continued growth. Dr. Tang completed his postdoctoral research training at the University of Chicago and holds a Ph.D. in Physical Chemistry from the University of California, Davis.
“We are very pleased to recognize Xiaonan’s outstanding contributions and leadership with this well-deserved promotion,” said Dr. John Lin, Co-CEO of Frontage. “His ability to combine scientific expertise with operational excellence has been instrumental in strengthening our bioanalytical services. I am confident that in his new role, Xiaonan will continue to drive innovation, enhance our capabilities, and support Frontage’s long-term strategic growth.”
“I am honored to take on this new role at Frontage,” said Dr. Tang. “Having grown with the Company over the years, I am proud of what our team has accomplished. I look forward to continuing to advance our bioanalytical capabilities, foster innovation, and deliver high-quality solutions to support our clients’ drug development programs.”
About Frontage
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRO/CDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
SOURCE Frontage Laboratories, Inc.